B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

EPHB2

MOLECULAR TARGET

EPH receptor B2

UniProt: P29323NCBI Gene: 204828 compounds

EPHB2 (EPH receptor B2) is targeted by 28 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting EPHB2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1sb 2035804.92136
2foretinib4.3476
3tozasertib4.3375
4vandetanib4.3073
5ponatinib4.2670
6nilotinib4.1764
7bosutinib4.0858
8doramapimod4.0657
9canertinib3.5333
10tae 6843.4330
11fedratinib3.4029
12linifanib3.3327
13saracatinib3.3327
14dasatinib anhydrous3.0921
15lestaurtinib3.0420
16danusertib2.9418
17r 4062.8316
18milciclib2.7715
19tivozanib2.6413
20ast 4872.5612
21poziotinib2.4811
22rebastinib2.208
23golvatinib2.208
24cyc 1162.087
25bafetinib1.956
26sapitinib1.956
27Sorafenib1.614
28Dasatinib0.691

About EPHB2 as a Drug Target

EPHB2 (EPH receptor B2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 28 compounds with documented EPHB2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

EPHB2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.